FLURAZEPAM
|
- $24 - $860
- Product name: FLURAZEPAM
- CAS: 17617-23-1
- MF: C21H23ClFN3O
- MW: 387.88
- EINECS:241-591-7
- MDL Number:MFCD00057324
- Synonyms:2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-chloro-1-(2-(diethylamino)ethyl)-5-(o-fluorophenyl)-;2H-1,4-Benzodiazepin-2-one, 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-;2H-1,4-Benzodiazepin-2-one, 7-chloro-1-[2-(diethylamino)ethyl]-5-(o-fluorophenyl)-1,3-dihydro-;2h-1,4-benzodiazepin-2-one,1,3-dihydro-7-chloro-1-(2-(diethylamino)ethyl)-5-( ;7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1h-1,4-benzodiazepin-2( ;7-Chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1H-1,4-benzodiazepin-2(3H)-one;7-Chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one;7-Chloro-1-[2-(diethylamino)ethyl]-5-(o-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one
6 prices
Selected condition:
Brand
- AHH
- Cayman Chemical
- Sigma-Aldrich
Package
- 1mg
- 5mg
- 25mg
- 1mL
- 5g
- ManufacturerAHH
- Product numberMT-51860
- Product descriptionFlurazepam 97%
- Packaging5g
- Price$860
- Updated2026-05-26
- Buy
- ManufacturerCayman Chemical
- Product number18160
- Product descriptionFlurazepam (CRM)
- Packaging1mg
- Price$24
- Updated2026-04-30
- Buy
- ManufacturerCayman Chemical
- Product number16190
- Product descriptionFlurazepam ≥98%
- Packaging5mg
- Price$60
- Updated2023-06-20
- Buy
- ManufacturerCayman Chemical
- Product number41590
- Product descriptionFlurazepam ≥98%
- Packaging5mg
- Price$65
- Updated2026-04-30
- Buy
- ManufacturerCayman Chemical
- Product number41590
- Product descriptionFlurazepam ≥98%
- Packaging25mg
- Price$260
- Updated2026-04-30
- Buy
- ManufacturerSigma-Aldrich
- Product numberF-003
- Product descriptionFlurazepam solution 1.0?mg/mL in methanol, ampule of 1?mL, certified reference material, Cerilliant?
- Packaging1mL
- Price$28.4
- Updated2026-04-30
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| AHH | MT-51860 | Flurazepam 97% | 5g | $860 | 2026-05-26 | Buy |
| Cayman Chemical | 18160 | Flurazepam (CRM) | 1mg | $24 | 2026-04-30 | Buy |
| Cayman Chemical | 16190 | Flurazepam ≥98% | 5mg | $60 | 2023-06-20 | Buy |
| Cayman Chemical | 41590 | Flurazepam ≥98% | 5mg | $65 | 2026-04-30 | Buy |
| Cayman Chemical | 41590 | Flurazepam ≥98% | 25mg | $260 | 2026-04-30 | Buy |
| Sigma-Aldrich | F-003 | Flurazepam solution 1.0?mg/mL in methanol, ampule of 1?mL, certified reference material, Cerilliant? | 1mL | $28.4 | 2026-04-30 | Buy |
Properties
Melting point :77-82°
Boiling point :551.4±50.0 °C(Predicted)
Density :1.2089 (estimate)
Flash point :9℃
storage temp. :2-8°C
solubility :45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: <6 mg/mL
pka :pKa 1.90±0.05(H2O) (Uncertain);8.16±0.05 (Uncertain)
form :solid
color :light yellow
EPA Substance Registry System :2H-1,4-Benzodiazepin-2-one, 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro- (17617-23-1)
Boiling point :551.4±50.0 °C(Predicted)
Density :1.2089 (estimate)
Flash point :9℃
storage temp. :2-8°C
solubility :45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: <6 mg/mL
pka :pKa 1.90±0.05(H2O) (Uncertain);8.16±0.05 (Uncertain)
form :solid
color :light yellow
EPA Substance Registry System :2H-1,4-Benzodiazepin-2-one, 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro- (17617-23-1)
Safety Information
| Symbol(GHS): |
![]() ![]()
|
|||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Danger | |||||||||||||||||||||
| Hazard statements: |
|
|||||||||||||||||||||
| Precautionary statements: |
|
Description
Flurazepam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pam (CRM) pamRelated product price
-
1,3-Dihydro-5-phenyl-1,4-benzodiazepin-2-one
$26-2500 -
Benzophenone imine
$6-3343.7 -
Nordazepam
$24-1470






